

Entitlement Offer - Results

1 September 2020, Melbourne: Rhythm Biosciences Limited (ASX: RHY or "Rhythm") advises that the non-renounceable pro rata offer (**Entitlement Offer**) detailed in the Disclosure Document announced to the ASX on 31 July 2020 closed on 28 August 2020.

The Company has received valid entitlement applications for 49,477,059 new shares comprised of the following:

Entitlements taken up	49,477,059	\$2,968,623.54
Shortfall shares	10,973,011	\$658,380.66
Total	60,450,070	\$3,627,004.20

The Offer is not underwritten, however the Company received commitments to subscribe for any shortfall under the Offer from the Shortfall Investors. The shortfall will be allocated in accordance with section 5.3 of the Disclosure Document.

Mr Glenn Gilbert, Chief Executive Officer of Rhythm commented, "on behalf of the Board and executive, I would like to thank shareholders for their continued strong support, with in excess of 80% of eligible shareholders participating. The team looks forward to progressing the Company's development pathway and commercialisation aims for the ColoSTAT[®] test, which should add value to all stakeholders along with the community at large."

The results of the Entitlement Offer are as follows:

	Number of Shares
Existing shares on issue prior to the Entitlement Offer	115,862,500
Entitlements taken up	49,477,059
Shortfall Shares to be allocated	10,973,011
Total shares to be issued pursuant to the Entitlement Offer	176,312,570

The funds raised by the Entitlement Offer will be used by the Company as set out in the Disclosure Document released to the ASX on the 31 July 2020. The new shares are expected to be issued on 3 September 2020.

Released with the authority of the Board.

Adrien Wing Company Secretary

Rhythm Biosciences ACN: 619 459 335 ASX: RHY **Issued Capital** 115,862.500 Shares 3,000,000 Options Australian Registered Office Level 2, 480 Collins Street Melbourne VIC 3000 www.rhythmbio.com

Directors

Otto Buttula – Chairman of the Board Trevor John Lockett – Executive Director Louis James Panaccio – Non-Executive Director David John White – Non-Executive Director Eduardo Vom – Non-Executive Director